135 related articles for article (PubMed ID: 23327685)
1. Ovulatory effects of flutamide in the polycystic ovary syndrome.
Paradisi R; Fabbri R; Battaglia C; Venturoli S
Gynecol Endocrinol; 2013 Apr; 29(4):391-5. PubMed ID: 23327685
[TBL] [Abstract][Full Text] [Related]
2. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
[TBL] [Abstract][Full Text] [Related]
3. Hormonal effects of flutamide in young women with polycystic ovary syndrome.
De Leo V; Lanzetta D; D'Antona D; la Marca A; Morgante G
J Clin Endocrinol Metab; 1998 Jan; 83(1):99-102. PubMed ID: 9435423
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
5. The effect of androgen blockade on granulosa cell estradiol production after follicle-stimulating hormone stimulation in women with polycystic ovary syndrome.
Mehta RV; Malcom PJ; Chang RJ
J Clin Endocrinol Metab; 2006 Sep; 91(9):3503-6. PubMed ID: 16804036
[TBL] [Abstract][Full Text] [Related]
6. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
[TBL] [Abstract][Full Text] [Related]
7. Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders.
Filicori M; Flamigni C; Meriggiola MC; Ferrari P; Michelacci L; Campaniello E; Valdiserri A; Cognigni G
J Clin Endocrinol Metab; 1991 May; 72(5):965-72. PubMed ID: 1902487
[TBL] [Abstract][Full Text] [Related]
8. Relevance of an opioid, noscapine in reducing cystogeneses in rat experimental model of polycystic ovary syndrome.
Priyadarshani A
J Endocrinol Invest; 2009 Nov; 32(10):837-43. PubMed ID: 19609106
[TBL] [Abstract][Full Text] [Related]
9. Metformin treatment is effective in obese teenage girls with PCOS.
De Leo V; Musacchio MC; Morgante G; Piomboni P; Petraglia F
Hum Reprod; 2006 Sep; 21(9):2252-6. PubMed ID: 16785260
[TBL] [Abstract][Full Text] [Related]
10. Metformin versus acarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study.
Hanjalic-Beck A; Gabriel B; Schaefer W; Zahradnik HP; Schories M; Tempfer C; Keck C; Denschlag D
Gynecol Endocrinol; 2010 Sep; 26(9):690-7. PubMed ID: 20626240
[TBL] [Abstract][Full Text] [Related]
11. Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition.
Hale GE; Hughes CL; Burger HG; Robertson DM; Fraser IS
Menopause; 2009; 16(1):50-9. PubMed ID: 18978637
[TBL] [Abstract][Full Text] [Related]
12. Low estradiol-to-testosterone ratio is associated with oligo-anovulatory cycles and atherogenic lipidic pattern in women with polycystic ovary syndrome.
Amato MC; Verghi M; Nucera M; Galluzzo A; Giordano C
Gynecol Endocrinol; 2011 Aug; 27(8):579-86. PubMed ID: 20608809
[TBL] [Abstract][Full Text] [Related]
13. Effects of unkei-to, an herbal medicine, on endocrine function and ovulation in women with high basal levels of luteinizing hormone secretion.
Ushiroyama T; Ikeda A; Sakai M; Hosotani T; Suzuki Y; Tsubokura S; Ueki M
J Reprod Med; 2001 May; 46(5):451-6. PubMed ID: 11396371
[TBL] [Abstract][Full Text] [Related]
14. Irregular cycles and steroid hormones in polycystic ovary syndrome.
Doi SA; Al-Zaid M; Towers PA; Scott CJ; Al-Shoumer KA
Hum Reprod; 2005 Sep; 20(9):2402-8. PubMed ID: 15932911
[TBL] [Abstract][Full Text] [Related]
15. Antiandrogen Treatment Ameliorates Reproductive and Metabolic Phenotypes in the Letrozole-Induced Mouse Model of PCOS.
Ryan GE; Malik S; Mellon PL
Endocrinology; 2018 Apr; 159(4):1734-1747. PubMed ID: 29471436
[TBL] [Abstract][Full Text] [Related]
16. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women.
Ibáñez L; de Zegher F
Hum Reprod Update; 2006; 12(3):243-52. PubMed ID: 16407452
[TBL] [Abstract][Full Text] [Related]
17. Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin-releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase.
Sagnella F; Apa R; Guido M; Villa P; Spadoni V; Miceli F; Lanzone A
Fertil Steril; 2009 May; 91(5):1857-63. PubMed ID: 18538325
[TBL] [Abstract][Full Text] [Related]
18. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
19. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F
Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
[TBL] [Abstract][Full Text] [Related]
20. Intake of vinegar beverage is associated with restoration of ovulatory function in women with polycystic ovary syndrome.
Wu D; Kimura F; Takashima A; Shimizu Y; Takebayashi A; Kita N; Zhang G; Murakami T
Tohoku J Exp Med; 2013 May; 230(1):17-23. PubMed ID: 23666047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
